Methylene blue for the prevention and treatment of ifosfamide-induced encephalopathy: clinical effectiveness and safety
CADTH
Record ID 32015000198
English
Authors' recommendations:
One non-randomized study regarding the clinical effectiveness of methylene blue for the prevention of ifosfamide-induced encephalopathy was identified.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/dec-2014/RA0691%20Methylene%20Blue%20for%20Encephalopathy%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Methylene Blue
- Ifosfamide
- Dose-Response Relationship, Drug
- Brain Diseases
- Infusions, Intravenous
- Chemotherapy, Adjuvant
- Antineoplastic Agents, Alkylating
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.